{"article_title": "340B Omnibus Guidance Could Lead To Increased Drug Costs", "article_keywords": ["340b", "patient", "increased", "lead", "eligible", "omnibus", "guidance", "drug", "costs", "health", "york", "test", "view", "previous"], "article_url": "http://www.law360.com/articles/698492/340b-omnibus-guidance-could-lead-to-increased-drug-costs", "article_text": "340B Omnibus Guidance Could Lead To Increased Drug Costs\n\nLaw360, New York (September 3, 2015, 11:35 AM ET) -- New guidance from the U.S. Health Resources Services Administration clarifying certain definitions integral to the 340B Drug Pricing Program will significantly limit the number of patients eligible to receive 340B drugs, resulting in substantial increases in prescription drug costs for many 340B-participating health care providers.[1] The guidance contains a six-part test for an \u201celigible patient,\u201d substantially more onerous to meet than HRSA\u2019s previous three-part test and directly conflicting with previous guidance issued by HRSA. If this new \u201cpatient\u201d definition is finalized, we expect that many 340B covered...\n\nTo view the full article, register now.", "article_metadata": {"description": "New guidance from the U.S. Health Resources Services Administration clarifying certain definitions integral to the 340B Drug Pricing Program will significantly limit the number of patients eligible to receive 340B drugs, leading to substantial increases in drug costs for many participating health care providers and potentially significant economic consequences, says Kristi Kung at Pillsbury Winthrop Shaw Pittman LLP.", "apple-itunes-app": "app-id=934560389, app-argument=law360://www.law360.com/articles/698492/340b-omnibus-guidance-could-lead-to-increased-drug-costs", "csrf-token": "0gqpkCMTd0SJyYxEA0vxLr3rr6qCO+S4DB5HO5EhSFW9zWwSL+LjMB+3/pXjFGv2FGo9n8hUlV4r1EQws42fFw==", "csrf-param": "authenticity_token", "og": {"url": "http://www.law360.com/articles/698492/340b-omnibus-guidance-could-lead-to-increased-drug-costs", "image": "https://www.law360.com/images/360.png", "type": "website", "title": "340B Omnibus Guidance Could Lead To Increased Drug Costs - Law360"}, "viewport": "width=device-width, initial-scale=1.0"}, "_id": "\"57477af46914bd0286fd894a\"", "article_summary": "340B Omnibus Guidance Could Lead To Increased Drug CostsLaw360, New York (September 3, 2015, 11:35 AM ET) -- New guidance from the U.S. Health Resources Services Administration clarifying certain definitions integral to the 340B Drug Pricing Program will significantly limit the number of patients eligible to receive 340B drugs, resulting in substantial increases in prescription drug costs for many 340B-participating health care providers.\n[1] The guidance contains a six-part test for an \u201celigible patient,\u201d substantially more onerous to meet than HRSA\u2019s previous three-part test and directly conflicting with previous guidance issued by HRSA.\nIf this new \u201cpatient\u201d definition is finalized, we expect that many 340B covered...To view the full article, register now."}